Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: TheBodyPRO.com Covers AIDS 2014
  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary
  • PDF PDF

Maraviroc Approved for First-Line Therapy

Winter/Spring 2010

In late November, the U.S. Food and Drug Administration (FDA) approved the first CCR5 antagonist, maraviroc (Selzentry), for treatment-naive individuals with exclusively CCR5-tropic virus (determined using the Trofile assay). Given the first-line approval of the first integrase inhibitor, raltegravir, this past July, people starting ART now have a wider array of effective and well-tolerated options.

The MERIT trial initially suggested that maraviroc did not work quite as well as efavirenz (Sustiva) for treatment-naive people with high viral load, but an analysis using the current, more sensitive Trofile assay found that the two drugs worked equally well after excluding participants originally misclassified as having only CCR5-tropic virus. Maraviroc is well-tolerated overall, and recent studies suggest that it may produce larger CD4 cell gains and reduce inflammation more than drugs from other classes (see "Inflammation, Immune Activation, and HIV").

Liz Highleyman (liz@black-rose.com) is a freelance medical writer based in San Francisco.



  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary
  • PDF PDF

This article was provided by San Francisco AIDS Foundation. It is a part of the publication Bulletin of Experimental Treatments for AIDS. Visit San Francisco AIDS Foundation's Web site to find out more about their activities, publications and services.
 
See Also
More on HIV Medications
More News and Research on Maraviroc (Selzentry, Celsentri)

No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Tools
 

Advertisement